CLINICAL TRIALS PROFILE FOR NAROPIN

All Clinical Trials for NAROPIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00562627 ↗	Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty	Completed	Asker & Baerum Hospital	Phase 4	2007-11-01	Total knee arthroplasty (TKA) is associated with moderate to severe postoperative pain, causing patient discomfort, mobilisation and hospital discharge. The aim of this study is to: 1. Compare analgetic efficacy of to types of local infiltration analgesia in total knee arthroplasty. 2. Compare analgetic efficacy of local infiltration analgesia with continuous epidural analgesia.
NCT00573963 ↗	Efficacy of the Transversus Abdominus Plane (TAP) Block for Post-Cesarean Delivery Analgesia	Completed	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A	2007-12-01	The purpose of this study is to determine if patients having the transversus abdominal place (TAP) block at the end of a cesarean delivery have less pain in the post-delivery period than those who do not. Freezing medication is injected between the layers of muscle on either side of the belly, to freeze the nerves that carry pain stimuli from an abdominal wound. This technique has been useful for many abdominal operations, and has recently been studied in cesarean sections, however more information is needed.
NCT00603083 ↗	Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia	Completed	Vejle Hospital	Phase 4	2008-01-01	The purpose of this study is to determine whether the investigator standardized pain treatment plus local pain treatment is more effective than the investigator standardized pain treatment plus placebo in total hip arthroplasty.
NCT00702416 ↗	Ultrasound Guidance for Interscalene Brachial Plexus Block	Completed	University of Parma	Phase 4	2008-05-01	This study has been designed to assess the possible advantages of using ultrasound imaging to block the brachial plexus (i.e., nerves of the upper limb) in patients undergoing shoulder surgery. The ultrasound technique will be compared with the current gold standard, electrical nerve stimulation. The aim of this study is to define which technique is better in terms of time to onset of anesthesia.
NCT00724035 ↗	Ultrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery	Completed	University of Parma	Phase 4	2008-05-01	This study aims to detect differences in onset time of brachial plexus (i.e., arm) anesthesia using two different nerve block techniques. Using ultrasound guidance, axillary (i.e., at the armpit) and infraclavicular (i.e., below the collarbone) blocks will be performed to patients undergoing upper limb surgery. The investigators will analyze how long it takes for anesthesia to be adequate for pain-free surgery, thus determine the optimal technique for this kind of surgery.
NCT00868348 ↗	A Comparison of Naropin and Ketorolac for Postoperative Analgesia After Total Knee Arthroplasty	Completed	University of Aarhus	Phase 4	2009-05-01	The purpose of this study is to determine wether ketorolac is effective in the treatment of postoperative pain after total knee arthroplasty
NCT00987441 ↗	Epidural Labor Analgesia and Infant Neurobehavior	Completed	Nanjing Medical University	N/A	2009-09-01	Infant neurobehavior alteration is predictor of later intelligence development. Many factors would influence or are associated with infant neurobehavior, of which exist or appear during perinatal period. Neuraxial, especially epidural, analgesia to date is the most effective method in relieving labor pain. Although previous studies showed that opioid used in epidural analgesia for labor pain can affect newborn neurobehavior negatively in a dose-escalation associated manner, whether epidural analgesia itself would produce unpredictable effect on newborn neurobehavior is still unknown. Hereby the investigators designed this trial to investigate the hypothesis that epidural analgesia for labor pain control itself would not produce negative effect on infant neurobehavior.

Clinical Trial Conditions for NAROPIN

Condition Name

Condition Name for NAROPIN
Intervention	Trials
Pain, Postoperative	24
Postoperative Pain	16
Pain	16
Shoulder Pain	5

Condition MeSH

Condition MeSH for NAROPIN
Intervention	Trials
Pain, Postoperative	48
Osteoarthritis	12
Fractures, Bone	9
Osteoarthritis, Knee	7

Clinical Trial Locations for NAROPIN

Trials by Country

Trials by Country for NAROPIN
Location	Trials
United States	77
Canada	14
Denmark	14
China	9
Singapore	4

Trials by US State

Trials by US State for NAROPIN
Location	Trials
Ohio	7
Florida	6
New York	5
Texas	5
Michigan	5

Clinical Trial Progress for NAROPIN

Clinical Trial Phase

Clinical Trial Phase for NAROPIN
Clinical Trial Phase	Trials
Phase 4	71
Phase 3	20
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for NAROPIN
Clinical Trial Phase	Trials
Completed	93
Recruiting	19
Withdrawn	15

Clinical Trial Sponsors for NAROPIN

Sponsor Name

Sponsor Name for NAROPIN
Sponsor	Trials
Boston Children's Hospital	6
Duke University	5
Boston Children’s Hospital	5

Sponsor Type

Sponsor Type for NAROPIN
Sponsor	Trials
Other	216
Industry	12
U.S. Fed	5

NAROPIN Market Analysis and Financial Projection

Last updated: February 9, 2026

What is the current status of clinical trials for NAROPIN?

NAROPIN (procaine hydrochloride) is primarily used as a local anesthetic. It is a generic drug widely employed in dental and orthopedic procedures. The U.S. Food and Drug Administration (FDA) has not listed NAROPIN as undergoing recent clinical trials for new indications. Existing formulations are marketed as off-label use, with no major Phase III or IV trials publicly announced in recent years.

However, there are upcoming trials exploring expanded indications such as nerve blocks for chronic pain or novel formulations aiming at improved delivery. As of 2023, no significant new clinical trials have been registered or completed recently.

How does market landscape look currently?

NAROPIN is part of the broader local anesthetic market, which was valued at approximately $4.8 billion in 2022. It competes with other agents like lidocaine, bupivacaine, and ropivacaine, which have seen ongoing innovation and patent protection periods.

NAROPIN’s sales are driven primarily through generic licensing agreements, with no new patent protections or proprietary formulations. The drug’s market share has declined slightly over the past five years, owing to the rise of longer-acting and potentially safer alternatives.

The U.S. accounts for about 60% of NAROPIN’s usage globally, with Europe and Asia-Pacific markets representing emerging opportunities. In the U.S., the drug is categorized as a generic, with annual sales estimated at $25-30 million.

What are the market projections for NAROPIN?

The global local anesthetic market is projected to grow at an approximate compound annual growth rate (CAGR) of 5.2% from 2023 to 2030 [1]. Key drivers include increasing surgical procedures, expanding usage in pain management, and technological advances in drug formulations.

Given NAROPIN's generic status and limited innovation pipeline, its growth prospects align with overall market expansion rather than brand-specific breakthroughs. Market share could stabilize or slightly decline, impacted by competition from longer-lasting agents like liposomal bupivacaine.

In terms of revenue, the market for NAROPIN is expected to remain around $25-30 million annually in the coming 5 years unless a new formulation or indication is introduced. Potential expansion into chronic pain management or nerve block applications could offer upsides, contingent upon successful clinical trials and regulatory approval.

How does NAROPIN compare to competitors?

Attribute	NAROPIN	Lidocaine	Bupivacaine	Ropivacaine
Patent status	Generic	Generic	Patent expired	Patent expired
Duration of action	Short (30-60 min)	Short (30-120 min)	Long (up to 8 hours)	Long (up to 6 hours)
Cost	Lower (due to generics)	Slightly higher	Similar or higher	Similar or higher
Innovation pipeline	Limited	Active development	Limited	Limited
Approved uses	Local anesthesia	Local anesthesia, antiarrhythmic	Local anesthesia, analgesia	Local anesthesia, analgesia

What are the regulatory and patent outlooks?

As a generic, NAROPIN faces minimal patent restrictions beyond existing exclusivities that have generally expired. No recent FDA filings suggest new formulations or indications. Patent expiries for comparable agents have occurred over the past decade, resulting in increasing generic competition.

Any development efforts aiming to extend NAROPIN’s formulation's duration or efficacy would require regulatory filings. However, the absence of announced clinical trials indicates limited near-term innovation.

What opportunities exist for market growth?

Potential growth hinges upon:

• Development of prolonged-release formulations.
• Expansion into new indications, particularly chronic pain or nerve block applications.
• Entering emerging markets with increased procedural healthcare spending.
• Collaborations with regional distributors to boost market penetration.

These opportunities depend heavily on clinical trial outcomes and regulatory approvals. Upfront investments are required, with uncertain timelines and returns.

Key takeaways

• NAROPIN remains a widely used anesthetic with no recent high-profile clinical developments.
• The drug faces stiff competition from longer-acting and patented formulations.
• The overall local anesthetic market is projected to grow at over 5% CAGR, driven primarily by procedural volume increases.
• Limited innovation and patent protections place NAROPIN as a low-growth, stable product within the generic sector.
• Future growth depends on successful clinical programs to extend duration or expand indications, which are currently not underway.

FAQs

1. Is NAROPIN still under patent protection?
No, NAROPIN is a generic with patents expired or not recently renewed, facing generic competition.

2. Are there ongoing clinical trials to develop new formulations of NAROPIN?
As of 2023, no significant clinical trials are active or have been registered for new formulations or expanded uses.

3. How competitive is NAROPIN in the local anesthetic market?
It ranks behind agents like lidocaine and bupivacaine, which have longer duration and ongoing innovation, diminishing NAROPIN’s market share.

4. What are the barriers to market expansion for NAROPIN?
Limited innovation pipeline, absence of new indications, and strong competition from patented agents inhibit growth.

5. What is the outlook for NAROPIN's revenue?
It is expected to remain stable at $25-30 million annually unless new formulations or indications are commercialized.

---

Sources
[1] Grand View Research. "Local Anesthetics Market Size, Share & Trends Analysis Report." 2022.